Site Search

... innovation needs to be considered from the genesis of targeted therapies. It’s well-documented that patients are missing key opportunities for biomarker testing, which looks for specific mutations of a cancer to determine the most effective therapy for their particular cancer. As we have learned ... is reaching every patient.  It’s equally important to consider patient access to targeted therapies. Assuming a patient has had appropriate biomarker testing, patient access to the therapies indicated by this testing is another potential barrier. Our health care system has to find ways ...